- Current report filing (8-K)
November 09 2010 - 4:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
:
November 9
, 2010
AVI
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
incorporation)
|
|
|
|
Identification No.)
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices, including zip code)
(425) 354-5038
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 2.02
Results of Operations and
Financial Condition.
On
November 9, 2010, AVI BioPharma, Inc. (the Company) announced via
press release the Companys results for the three and nine month periods ended September 30,
2010. A copy of the Companys press
release is attached hereto as Exhibit 99.1. The information in this Form 8-K and the
attached exhibit are furnished to, but not filed with, the Securities and
Exchange Commission.
Item 9.01
Financial Statements and
Exhibits.
(d) Exhibits.
Pursuant
to the rules and regulations of the Securities and Exchange Commission,
the attached exhibit is deemed to have been furnished to, but not filed with,
the Securities and Exchange Commission:
Exhibit Number
|
|
Description
|
99.1
|
|
Press
release, dated November 9, 2010, entitled AVI BioPharma Announces Third
Quarter 2010 Financial Results.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AVI BioPharma, Inc.
|
|
|
|
By:
|
/s/
J. David Boyle II
|
|
|
J. David Boyle II
|
|
|
Interim President and Chief Executive Officer, and
Senior Vice President and Chief Financial Officer
|
Date:
November 9, 2010
3
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
99.1
|
|
Press
release, dated November 9, 2010, entitled AVI BioPharma Announces Third
Quarter 2010 Financial Results.
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024